|
مقاله
|
Abstract
|
|
|
|
Title:
|
Effects of methotrexate in treatment of chronic central serous chorioretinopathy
|
|
Author(s):
|
Majid Abrishami, Maryam Hosseini, Amir Norouzpour
|
|
Presentation Type:
|
Poster
|
|
Subject:
|
Posterior Segment and Uveitis
|
|
Others:
|
|
|
Presenting Author:
|
|
|
Name:
|
Majid Abrishami
|
|
Affiliation :(optional)
|
Retina Research Center, Khatam-Al-Anbia Eye Hospital, Mashhad University of Medical Sciences
|
|
E mail:
|
abrishami.m@gmail.com
|
|
Phone:
|
05138433192
|
|
Mobile:
|
09154793944
|
|
|
|
|
Purpose:
|
Evaluation of oral methotrexate (MTX) in patients with chronic central serous chorioretinopathy (CSC).
|
|
Methods:
|
This study is an interventional, prospective, uncontrolled clinical trial of patients presenting with chronic symptomatic CSC. All patients treated with oral MTX 7.5 mg/week for 12 weeks, and monitored for 6 months. Best corrected visual acuity (BCVA), central macular thickness (CMT), SRF, and total macular volume recorded by monthly OCT were analyzed. Complete blood count and serum liver enzymes level were monitored.
|
|
Results:
|
23 eyes of 23 consecutive patients were included with mean age 42 years. Mean duration of CSC was 13 months (3-36 months). Mean BCVA improved from 20/40 at baseline to 20/30 at 3 months, and 28/40 at 6 months (P=0.000 and 0.001 respectively). CMT improved from 375 µm at baseline to 278 µm and 265 µm at 3 and 6 months respectively (P=0.000 and 0.002 respectively). Total macular volume improved from 9.33 mm3 at baseline to 8.48 mm3 and 8.31 mm3 at 3 and 6 months respectively (P=0.000 and 0.000 respectively). Thirteen eyes (62%) achieved complete resolution of SRF. No MTX-associated toxicity was detected.
|
|
Conclusion:
|
Low-dose oral MTX may be an alternative therapeutic option for the treatment of chronic CSC.
|
|
Attachment:
|
5928.pptx
|
|